“We are extremely pleased that The Medicine Maker is reporting on how EsoCap’s unique and innovative topical drug delivery system offers new treatment options for diseases of the esophagus,” said…
EsoCap AG has been recognised by the special issue of Life Sciences Review Europe as a top biotech start-up. “We are extremely pleased to have been chosen for the cover…
EsoCap AG announced today that the Mexican Patent and Trademark Office has issued a patent under number 383626, based on Patent Application No. MX/a/2017/007566. The patent is directed at the…
EsoCap AG has been featured in Fierce Pharma Online. “We are extremely pleased that Fierce Pharma Online reviewed EsoCap’s unique and innovative topical drug delivery system to the esophagus and…
EsoCap successfully closes a private financing round, with investments from existing and new investors The new funding was facilitated by EsoCap benefitting from a unique programme implemented by the Canton…
Randomized, placebo-controlled, double-blind Phase II trial to treat 42 patients ongoing in four European countries with ESO-101 ESO-101, EsoCap’s lead product candidate, consists of a capsule with a rolled, thin…
EsoCap’s targeted application technology drastically increases mucosal contact time and enables effective local treatment of various esophageal diseases for the first time Proof of principle in human established; Phase II…
The feature in the latest issue of the renowned Nature Research publication gives an insightful overview of EsoCap’s company profile and the current development stage of their novel platform technology…
EsoCap announced today that the novelty of their unique drug delivery technology has once again been confirmed by a patent, granted by the State of Israel, under number 252893, based…
EsoCap has announced that scientists from the University of Greifswald have published exciting data demonstrating the high level of acceptance of its novel drug delivery technology enabling targeted and long-lasting…
Malzgasse 9, CH-4052 Basel
